Medication Adherence Pattern for Benign Prostatic Hyperplasia: A Cross-Sectional Study

  • Jyoti Tara Manandhar Shrestha Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
  • Hem Nath Joshi Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
  • Prabin Neupane Kathmandu University School of Medical Sciences, Dhulikhel, Nepal
Keywords: Adherence, Benign prostate hyperplasia, Lower urinary tract symptoms


Introduction: Benign prostate hyperplasia is one of the most common diseases and a common cause of lower urinary tract symptoms in aging men. Various disease management approaches to optimize the patient’s long life and efficient status where patient adherence to the prescribed treatment plays a vital role. This study evaluated the medication adherence pattern of the patients to obtain successful treatment outcomes. Methods: A cross-sectional study was conducted in out-patient department of urology in a tertiary care hospital. Patients diagnosed with benign prostate hyperplasia were interviewed using a structured questionnaire. Results: The high expenses of medicine, fear of medication, lack of symptomatic relief were factors that showed statistically significant (p < 0.05) difference between adherent and non-adherent group. Similarly, the duration of diagnosis of the adherent group was significantly less than the non-adherent group including the pattern of physical activities (p < 0.05). Adherent group also had more participants working in business and services occupation compared to the non-adherent group. Conclusion: The general attitude (such as fear of medication and lack of symptomatic relief) is seen as major factors that affect adherent pattern in benign prostate hyperplasia patients. These issues can be solved using proper guidance. However, the cost of medicines also posts an immense issue for the non-adherent group.


Download data is not yet available.

Author Biographies

Jyoti Tara Manandhar Shrestha, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal

Associate Professor,

Department of Pharmacology.

Hem Nath Joshi, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal

Associate Professor,

Department of Urology.

Prabin Neupane, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal

Research Assistant,

Department of Pharmacology.


Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19 Suppl 1:10-7. PMID: 23089343

Raza I, Hassan N, Jafri A, Gul P. Relationship between Benign Prostatic Hyperplasia and International Prostatic Symptom Score. British Journal of Medicine & Medical Research. 2015;10(5):1-9. Available from:

Rył A, Rotter I, Miazgowski T, Słojewski M, Dołęgowska B, Lubkowska A, et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol Metab Syndr. 2015;7(0):94. PMID: 26516352. DOI:

Eryildirim B, Aktas A, Kuyumcuoglu U, Faydaci G, Tarhan F, Ozgül A. The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis. Int J Impot Res. 2010;22(6):349-54. PMID: 20981108. DOI:

Cindolo L, Pirozzi L, Sountoulides P, Fanizza C, Romero M, Castellan P, et al. Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol. 2015;15:96. PMID: 26391357. DOI:

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol. 2013;64(1):118-40. PMID: 23541338. DOI:

Tripathi K. Essentials of medical pharmacology. 7th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013. Available from:

Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol. 2010;184(3):1040-4. PMID: 20643424. DOI:

World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization. Report number: WHO/MNC/03.01, 2003. Available from:

Central Intelligence Agency. The World Factbook [Internet]. Nepal: 2016. Available from:

McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793- 803. PMID: 21420124. DOI:

Yağmur I, Turna B, Tekin A, Akıncıoğlu E, Sarsık B, Ulman İ. Benign prostatic hyperplasia: Case report of a 17-year-old. J Pediatr Urol. 2016;12(4):267.e1-267.e4. PMID: 27593922. DOI:

Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5(4):212-18. PMID: 21475707. DOI:

Windham GC, Mitchell P, Anderson M, Lasley BL. Cigarette Smoking and Effects on Hormone Function in Premenopausal Women. Environ Health Perspect. 2005;113(10):1285-90. PMID: 16203235. DOI:

Matzkin H, Soloway MS. Cigarette smoking: A review of possible associations with benign prostatic hyperplasia and prostate cancer. Prostate. 1993;22(4):277-90. PMID: 7684523. DOI:

Parsons JK. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms.

Curr Opin Urol. 2011;21(1):1-4. PMID: 21045705. DOI:

Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM, et al. Obesity Increases and Physical Activity Decreases Lower Urinary Tract Symptom Risk in Older Men: The Osteoporotic Fractures in Men Study. Eur Urol. 2011;60(6):1173-80. PMID: 21802828. DOI:

Muhammed S, Nagla S, Morten S, Asma E, Arja A. Illness perceptions and quality of life among tuberculosis patients in Gezira, Sudan. Afr Health Sci. 2015;15(2):385-93. PMID: 26124783. DOI:

Wabe N, Angamo M, Hussein S. Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. North Am J Med Sci. 2011;3(9):418-23. PMID: 22362451. DOI:

Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, et al. Associations of Serum Sex Steroid Hormone and 5-Androstane-3 ,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1823-32. PMID: 22879203. DOI:

Liu L, Zhao S, Li F, Li E, Kang R, Luo L, et al. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. J Sex Med. 2016;13(9):1297-1310. PMID: 27475241. DOI:

Sweileh WM, Zyoud SH, Abu Nab’a RJ, Deleq MI, Enaia MI, Nassar SM, et al. Influence of patients’ disease knowledge and beliefs about medicines on medication adherence: findings from a cross-sectional survey among patients with type 2 diabetes mellitus in Palestine. BMC Public Health. 2014;14:94. PMID: 24479638. DOI:

Miller TA, DiMatteo R. Importance of family/ social support and impact on adherence to diabetic therapy. Diabetes Metab Syndr Obes. 2013;6(0)421-6. PMID: 24232691. DOI:

De Nunzio C, Presicce F, Lombardo R, Trucchi A, Bellangino M, Tubaro A, et al. Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients’ care – a systematic review. BMC Urol. 2018;18(1):62. PMID: 29940928. DOI:

How to Cite
Manandhar Shrestha J, Joshi H, Neupane P. Medication Adherence Pattern for Benign Prostatic Hyperplasia: A Cross-Sectional Study. J Lumbini Med Coll [Internet]. 30Oct.2020 [cited 16Jun.2021];8(2):225-32. Available from:
Original Research Article